![]() |
|
|
Vol. 294, Issue 3, 983-990, September 2000
Centre for Gastroenterological Research, Department of Pathophysiology, University of Leuven, Leuven, Belgium (I.D., T.T., G.V.A., T.L.P.); and Genetics Institute, Andover, Massachusetts (J.C.K.)
| |
Abstract |
|---|
|
|
|---|
We studied the effect of recombinant human interleukin-11 (rhIL-11), a cytokine with protective effects against injury to the intestinal mucosa, on inflammatory changes in the muscle layers of the gut, in rabbits with colitis. A single dose of rhIL-11 (4, 40, or 720 µg/kg) was given 1 h before colitis was induced with 135 mg/kg 2,4,6-trinitrobenzene sulfonic acid (TNBS), followed by a continuous s.c. administration of 4, 40, or 720 µg/kg · day rhIL-11 or saline for 5 days. Colitis affected mucosal architecture, general mechanical properties (passive tension increased with 12.3 g/mm2, optimal stretch decreased with 26%), and collagen content (decreased from 366 ± 25 to 237 ± 13 µg/mg of protein). Changes in passive tension and collagen content were normalized by the highest and lowest dose of rhIL-11, respectively, but neither dose could normalize the optimal stretch. Colitis also decreased maximal contractile tension in response to acetylcholine (ACh), motilin, substance P (SP), K+, and prostaglandin E2 but this was normalized with 40 µg/kg · day (motilin, SP) and 720 µg/kg · day (ACh, K+) rhIL-11 but not for prostaglandin E2. For motilin and SP, receptor density was decreased in colitis and normalized in treated rabbits. Colitis also increased the contractile potency toward ACh, an effect already reversed by rhIL-11, 4 µg/kg · day. In conclusion, rhIL-11 partially normalizes disturbed tension generation in experimental colitis. The use of this cytokine in the treatment of irritable bowel disease may contribute to the restoration of motor dysfunction.
| |
Introduction |
|---|
|
|
|---|
Interleukin
(IL)-11 was originally discovered as the factor present in the
supernatants of transformed stromal cells that stimulated the
proliferation of IL-6-dependent plasmacytoma cells (Paul et al., 1990
).
In accordance with this finding, most studies of IL-11 have focused on
its role in hematopoiesis (Du and Williams, 1994
). IL-11 has, however,
been shown to have a variety of other effects, including the ability to
stimulate the acute phase response, to augment the production of
metalloproteinase inhibitors, to stimulate the proliferation of
hippocampal neuronal progenitor cells, to increase Ig production, to
inhibit the genesis of adipocytes, to activate osteoclasts, to reduce
the expression of proinflammatory cytokines [particularly tumor
necrosis factor-
(TNF-
)], and to regulate epithelial cell
proliferation (for review, see Du and Williams, 1997
).
IL-11 treatment also has protective effects on intestinal mucosa. It
has been shown to prevent or reverse mucosal damage caused by
experimental ischemic bowel necrosis (Du et al., 1997
) and burn in mice
(Schindel et al., 1997
). It was also effective in a rat short-bowel
model (Liu et al., 1996
) and in a hamster model of mucositis induced by
chemotherapy (Sonis et al., 1995
).
Recently, a protective effect of IL-11 was demonstrated in acute and
chronic inflammatory models of colitis in rats. IL-11 reduced damage
caused by intracolonic administration of acetic acid (Keith et al.,
1994
) and 2,4,6-trinitrobenzene sulfonic acid (TNBS; Qiu et al., 1996
)
and reduced the severity of colitis in HLA-B27 transgenic rats (Keith
et al., 1994
). In a rabbit model of endotoxemia, IL-11 treatment
prevented damage of the intestinal mucosa induced by lipopolysaccharide
(Misra et al., 1996
).
The mechanism by which IL-11 reduces epithelial damage in these models
of intestinal injury remains largely unknown. Orazi et al. (1996)
showed that IL-11 exerts its potent effect on the recovery of the small
intestinal mucosa of mice, after treatment with chemotherapy and
radiation, by increasing proliferation and by suppressing apoptosis of
the crypt cells. Castagliuolo et al. (1997)
found that the protective
effect of IL-11 on the inflammatory diarrhea induced by
Clostidium difficile toxin A in rats may be due to an
inhibition of the release of inflammatory mediators from mucosal mast
cells and macrophages. In accordance with this hypothesis, Trepicchio
et al. (1996)
demonstrated that IL-11 reduced the
lipopolysaccharide-induced production of proinflammatory cytokines (TNF-
, IL-1
, IL-12, and interferon-
) and of nitric oxide from macrophages. These observations have prompted further studies toward
the clinical application of the protective effects of the cytokine
against injury to the intestinal mucosa in Crohn's disease (CD). It
was reported recently that short-term treatment with recombinant human
interleukin-11 (rhIL-11) is well tolerated and appears effective in
inducing remission in a subset of patients with active CD (Sands et
al., 1999
).
Besides mucosal damage, inflammation is known to affect the deeper,
neuromuscular layers of the gut wall as well, but no data are available
on the effects of IL-11 on this process. We have recently shown that
TNBS-induced colitis in rabbits changes the general mechanical
properties of the smooth muscle but also decreases the contractile
response of the strips by affecting receptor-mediated pathways
(Depoortere et al., 1999
). The aim of this study was to evaluate the
effect of IL-11 on the inflammatory lesions and on the changes in
contractile response toward receptor-specific [motilin, acetylcholine
(ACh), substance P (SP), prostaglandin E2
(PGE2)] and receptor-independent (KCl) stimuli.
ACh is the classical excitatory neurotransmitter in the gut. SP was
chosen because it may act as a mediator of neurogenic inflammation
during inflammatory bowel disease (IBD) and motilin because it is an important endocrine regulator of gastrointestinal motility. For motilin
and SP the effect of IL-11 treatment on contractile activity was
correlated with changes in receptor density. In addition the effect of
IL-11 treatment on changes in the contractile response to an
inflammatory mediator with direct contractile effects,
PGE2, also was evaluated.
| |
Materials and Methods |
|---|
|
|
|---|
Experimental Design
Twenty-five New Zealand White rabbits of either gender (2.5-3 kg) were randomly divided into five groups of five animals each. In four groups, colitis was induced by TNBS and the animals were treated with saline, or 4, 40, or 720 µg/kg · day recombinant human IL-11 (rhIL-11). The fifth group served as a control group. rhIL-11 was kindly provided by Dr. J. Keith from the Genetics Institute (Andover, MA).
Animal Treatment
One hour before the induction of colitis, rabbits received an
s.c. injection of 4, 40, or 720 µg/kg rhIL-11 or saline. Rabbits were
anaesthetized and colitis was induced by intrarectal administration of
a dialysis bag filled with 135 mg/kg TNBS (Fluka, Buchs, Switzerland) in 50% ethanol for 1 h according to the method described
previously (Percy et al., 1993
). During the anesthesia an osmotic pump
(Alza Corporation, Palo Alto, CA) filled with rhIL-11 or saline was implanted s.c. to deliver rhIL-11 or saline continuously for 5 days. At
the end of the treatment period rabbits were sacrificed. The distal
colon was removed and rinsed with 0.9% NaCl. All procedures were
approved by the Ethical Committee for Animal Experiments of the Belgian
Ministry of Agriculture (approval number LA1210225).
Histological Evaluation of Colitis
Segments of the distal colon taken at 5 and 40 cm from the
rectum were snap-frozen in 2-methylbutane at
30°C. Cryostat
sections (5 µm) were stained with H&E.
Determination of Total Collagen Content
Collagen content was determined by a colorimetric method (Coats
et al., 1996
). A piece of colon (100 mg) taken 5 cm from the rectum was
hydrolyzed in 6 N HCl for 22 h at 110°C. The hydrolysate was
lyophilized and dissolved in citric-phosphate buffer. Chloramine T (75 µl, 0.177 M) and Erlich's reagent (75 µl) were added to the sample
(50 µl) in the well of an enzyme-linked immunosorbent assay plate.
Standards of hydroxyproline (0-50 µg/ml) were treated similarly. The
enzyme-linked immunosorbent assay plate was incubated at 75°C for 16 min under constant shaking. The absorbance of the samples was then read
at 550 nm. The protein content of the hydrolysates was determined
according to the method of Lowry et al. (1951)
. The ratio of the weight
of collagen/weight of hydroxyproline was considered to be 7.46. Results
are expressed as micrograms collagen per milligram of protein.
Expression of TNF-
, IL-1
, IL-Receptor Antagonist (IL-RA), and
Cyclooxygenase-2 (COX-2) by Semiquantitative Reverse
Transcription-Polymerase Chain Reaction (PCR)
Total RNA was prepared from the mucosa and the muscle layer of
the colon with TRIzol Reagent (Life Technologies, Grand Island, NY). Single-stranded cDNA was synthesized with 200 U of
superscript II RNase H
reverse transcriptase
(Life Technologies) and oligo(dT) (25 µg/ml; Life Technologies) as
primer. The obtained cDNA served as a template for the PCR, consisting
of 30 (TNF-
), 29 (IL-1
), 27 (IL-RA), and 32 cycles (COX-2) of
amplification (95°C for 1', 58°C for 1', 72°C for 1' with a
final extension duration of 10' at 72°C) and with 1.5 U of
Taq DNA polymerase (Pharmacia Biotech, Uppsala, Sweden).
Primers for rabbit TNF-
(forward: 5'-CCACCACTTAGAAACCTGGAC-3', reverse: 5'-CGCTGAGCTTCCAAATAAATAC-3'), for rabbit IL-1
(forward: 5'-TGAAGAGCTGCTTCCAGGAC-3', reverse: 5'-TGGGCAGACTCAAATTCCAG-3'), for
rabbit IL-RA (forward: 5'-TCTGGGATGTTAACCAGAAG-3', reverse: 5'-AGTAGAACTTGGTGACCACG-3'), and for rabbit COX-2 (forward:
5'-CACTACAACTACAAGAGCTGGG-3', reverse: 5'-ATCAAACCAGGCACCAGAC-3') were
selected on the basis of the sequences published by Ito et al. (1986)
,
Mori et al. (1988)
, Goto et al. (1992)
, and Guan et al. (1997)
,
respectively. For semiquantitative assessment, primers of the rabbit
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH;
forward: 5'-TGATCCATTCATTGACCTCC-3', reverse
5'-GTGGATTCCACCACGTACTC-3'; Applequist et al., 1995
) were added. PCR
products were analyzed on a 1.2% agarose gel, visualized with ethidium
bromide, and photographed. The density of the bands was determined by
image analysis with the ImageMaster 1D software (Pharmacia Biotech).
The results are expressed as the ratio of intensity of the compound of
interest to the intensity of the housekeeping gene.
Contraction Studies
Approximately 8 cm from the rectum, a piece of colon of 5 cm was
removed. Circular strips of 0.2 × 2.5 cm were cut, freed from
mucosa, and suspended along their circular axis in a tissue bath filled
with HEPES buffer (11.6 mM HEPES, 137 mM NaCl, 5.9 mM KCl, 1.2 mM
CaCl2, 1.2 mM MgCl2, 11.5 mM glucose) at pH 7.4 and the response of the strips was measured
either isotonically or isometrically as previously described
(Depoortere et al., 1999
).
Isotonic Measurements.
Cumulative dose-response curves
toward ACh (10
8-10
4
M), motilin (10
9-10
6
M), SP (10
10-10
6 M),
and PGE2
(10
9-10
5 M) were
established. Results are expressed relative to a supramaximal dose of
ACh (10
4 M) added at the end of the
dose-response curves. Calculations were performed with the WINDAQ/EX
playback software (Dataq Instruments, Akron, OH). The
pEC50 values were derived from the
concentration-response curves by linear interpolation.
Isometric Measurements.
Length-tension relationships of the
strips were established. Muscle strips were stretched with 5%
increments of the initial length to a maximum stretch of 100% of the
initial length. The passive tension that developed in response to
stretch was measured for each increment in length. A contraction was
then elicited by addition to the bathing medium of either maximally
effective doses of ACh (10
4 M), motilin
(10
7 M), SP (10
7 M), or
K+ (140 mM). This contraction, above the passive
tension, was taken as the active tension. Optimal stretch
(Lo) was defined as the degree of
stretch that gave the maximum response to a contractile agent. The
magnitude of the tension was expressed in grams and normalized for the
cross-sectional area of the strip.
Receptor-Binding Studies
Motilin.
Colonic smooth muscle tissue freed from mucosa and
serosa was finely minced and homogenized in sucrose buffer with
inhibitors. Binding of
125I-Nle13-porcine motilin
was studied in washed 1000g fractions of the tissue
homogenates as previously described (Bormans et al., 1986
).
SP.
The procedure of Burcher et al. (1986)
was followed to
determine SP binding. The supernatant of the 1,000g
fractions used for motilin receptor-binding studies was further
centrifuged at 48,000g and the pellet was resuspended in 50 mM Tris-HCl (pH 7.4, 10 mM EDTA, 300 mM KCl) for 1 h at 4°C.
After centrifugation the pellets were washed and resuspended in
incubation buffer (50 mM Tris-HCl, pH 7.4; 3 mM
MnCl2; 200 mg/l BSA; 2 mg/l chymostatin; 4 mg/l
leupeptin; 40 mg/l bacitracin) containing 20 pM
125I-SP labeled with Bolton and Hunter Reagent
(Amersham, Amersham, UK) and increasing concentrations of unlabeled SP
and incubated for 30 min at 25°C. Membrane-bound SP was separated by centrifugation.
Statistical Analysis
Data are represented as mean ± S.E. Dose-dependent effects of rhIL-11 were compared with one-way ANOVA. Specific comparisons were made by calculating appropriate t values. Significance was accepted at the 5% level.
| |
Results |
|---|
|
|
|---|
Effect of rhIL-11 Treatment on Appearance of Colitis
Induction of colitis caused a loss of body weight that amounted to
333 ± 28 g (12.5% of their initial weight). Treatment with rhIL-11 could not reverse this effect, in contrast the highest dose of
rhIL-11 (720 µg/kg · day) significantly (P < .005) enhanced body weight loss to 483 ± 17 g compared with
nontreated inflamed rabbits (Fig. 1).
|
Inflammation increased the cross-sectional area of the distal colon (5 cm from the rectum) from 31.6 ± 2.6 to 66.2 ± 3.1 mm2. A similar increase in cross-sectional area was observed in the second, more proximal part, of the distal colon (40 cm from the rectum). rhIL-11 treatment dose dependently decreased this effect to normal values in both parts (Fig. 1). However, in the more proximal part the effect was already normalized with the dose of 40 µg/kg · day rhIL-11, whereas in the distal part a dose of 720 µg/kg · day was needed.
Histology.
Figure 2 shows an H&E
staining of colonic sections from inflamed rabbits treated with saline,
4 µg/kg · day, 40 µg/kg · day, or 720 µg/kg · day of
rhIL-11. The sections of rabbits treated with saline and with the
lowest dose of rhIL-11 show a loss of mucosal haustration and folding
and a distortion of the architecture of the mucosa. The lamina propria
cellular infiltrate is increased in intensity and is transmucosal in
location. Also apparent in these sections is the submucosal edema and
the segmentation of the circular muscle layer. These characteristics
resemble those previously described in inflamed rabbits (Depoortere et
al., 1999
). Treatment of rabbits with 40 µg/kg · day rhIL-11
restores the haustration and folding of the mucosa but increases the
height of the crypts. There is still evidence of an increased cellular infiltrate, basal in location, and of submucosal edema. However, this
dose of rhIL-11 restores the smooth muscle layer to a normal continuous
layer. Treatment with the highest dose of rhIL-11 results in
histological sections with a normal appearance.
|
Collagen Content.
Collagen content in tissue from noninflamed
rabbits was 366 ± 25 µg/mg of protein. Inflammation
significantly (P < .0005) decreased collagen content
to 237 ± 13 µg/mg of protein. Collagen content was already
normalized by the lowest dose of rhIL-11 (Fig. 3).
|
Inflammatory Mediators.
TNBS colitis increased the expression
of COX-2, IL-1
, and IL-RA mRNA in the colon (Fig.
4). IL-1
and IL-RA mRNA were increased 4.3- and 7.9-fold, respectively, in the mucosa but not COX-2 mRNA. In
the muscle layer COX-2 expression was increased 2.3-fold and a small
but significant increase also was observed for IL-1
and IL-RA. In
contrast, inflammation induced a small decrease of TNF-
mRNA
expression in both the colonic mucosa and muscle layer. During rhIL-11
treatment COX-2 mRNA and IL-1
expression remained increased in the
muscle layer and the mucosa, respectively, whereas IL-RA mRNA
expression was further enhanced in the mucosa (Fig. 4). Both IL-1
and IL-RA mRNA expression disappeared in the muscle layer, whereas
TNF-
mRNA levels were normalized during rhIL-11 treatment.
|
Effect of rhIL-11 Treatment on Contractile Properties of Colitic Strips
Passive Tension.
In inflamed colonic strips passive tension
was increased from 4.2 ± 0.9 to 16.5 ± 6.5 g/mm2. This increased tension was normalized by
720 µg/kg · day but not by 4 or 40 µg/kg · day rhIL-11
(Fig. 5).
|
Length-Tension Relationships to ACh, Motilin, SP, and KCl.
As
reported previously (Depoortere et al., 1999
), inflammation markedly
affected the length-tension relationship. Maximal tension, and the
stretch required to reach it, were markedly reduced. Treatment with
rhIL-11 reversed the effect on maximal tension but not on stretch and
this was observed for ACh (10
4 M), motilin
(10
7 M), SP (10
7 M),
and KCl (140 mM) but not for PGE2.
|
|
|
Contractile Potency.
Inflammation increased the contractile
potency (pEC50) for ACh from 5.90 ± 0.12 to
6.43 ± 0.08 and already the smallest dose of rhIL-11 normalized
the increased affinity for ACh. No changes were observed of the
potencies for motilin and SP (Table 1).
|
Effect on Response to PGE2. In noninflamed tissue, the response to PGE2 consisted of a small contraction amounting to 11 ± 4% of the response to a supramaximal dose of ACh, followed by a relaxation of the contraction by 22 ± 3%. In inflamed tissue the contraction was not significantly affected but the relaxation was reduced to 4 ± 2%. rhIL-11 treatment could not reestablish the PGE2-induced relaxation.
Effect of rhIL-11 Treatment on Motilin and SP Receptor Density
For motilin and SP the changes in maximal active tension after
treatment with rhIL-11 were related to changes in receptor density.
Inflammation per se decreased motilin receptor density and maximal
active tension by 71% (from 128 ± 21 to 37 ± 7 fmol/mg of
protein) and 58% (from 9.1 ± 0.6 to 3.8 ± 0.7 g/mm2), respectively (Fig.
9). Treatment with 4 µg/kg · day
rhIL-11 was without effect, but 40 µg/kg · day rhIL-11 normalized
both motilin receptor density and maximal active tension. Motilin
receptor affinity was not affected by the inflammatory process nor by
rhIL-11 treatment.
|
For SP, inflammation decreased the density of the high-affinity
receptor-binding site from 13.0 ± 2.9 to 1.6 ± 0.8 fmol/mg of protein and increased the affinity
(pKd) from 10.04 ± 0.08 to
10.83 ± 0.06. In contrast the affinity for the low-affinity receptor-binding site was not affected
[pKd: 8.00 ± 0.28 (control) versus 8.40 ± 0.18 (TNBS)] but the receptor density also was
decreased [522 ± 214 (control) versus 24 ± 11 (TNBS)
fmol/mg of protein]. Binding parameters were restored after treatment
with 40 µg/kg · day of rhIL-11, in parallel with the maximal
active tension induced by SP (Fig. 10).
|
| |
Discussion |
|---|
|
|
|---|
We investigated the effect of treatment with rhIL-11 on the inflammatory changes caused by TNBS-induced colitis on the neuromuscular layer of the colonic wall in rabbit. rhIL-11 improved the development of active tension toward contractile agents, which is decreased by inflammation. The dose of 40 µg/kg · day normalized the response to motilin and SP, and the highest dose (720 µg/kg · day) the response to ACh and KCl. The response to PGE2 was not normalized by rhIL-11. For motilin and SP changes in tension paralleled changes in receptor density. rhIL-11 also normalized the increased contractile potency to ACh. However, rhIL-11 was unable to ameliorate markedly the effect of inflammation on the general mechanical properties of the strips, despite the fact that collagen content was normalized by the lowest dose of rhIL-11. The increased passive tension was only reduced with the highest dose (720 µg/kg · day) of rhIL-11, whereas neither dose affected the reduced optimal stretch.
We also monitored mucosal parameters and inflammatory mediators to
document the inflammatory process. Earlier studies have shown that
rhIL-11 prevents mucosal damage in several inflammatory models and in
agreement with these studies we found that rhIL-11 treatment restored
the normal mucosal architecture. It was noted that rhIL-11 treatment
was not able to overcome the loss of body weight induced by
inflammation. In fact, the effect was enhanced with the highest dose of
rhIL-11. This is in contrast to studies in hamsters and rats where
IL-11 treatment diminished body weight loss induced by
chemotherapy-induced mucositis and by small bowel resection,
respectively (Sonis et al., 1995
; Liu et al., 1996
). Weight loss is
probably caused by a lack of appetite, and TNF-
and ILs are
established mediators of inflammation-induced anorexia (Plata-Salaman
et al., 1988
). However, because TNF-
mRNA expression was decreased
in rabbits with TNBS colitis it is unlikely that TNF-
is the major
inducer of the weight loss and rhIL-11 treatment normalized the
decrease but did not further enhance it. IL-1
expression was
increased by inflammation and remained increased during rhIL-11
therapy, but IL-RA, which may counteract the effect of IL-1
, also
was increased and enhanced by rhIL-11 therapy, so that a role of
IL-1
seems unlikely. The more pronounced weight loss observed with
the highest dose of rhIL-11 is therefore unexplained and requires
further study. It was shown by Plata-Salaman (1996)
that IL-6 subfamily
members, including IL-11, which are activators of the signal transducer
gp 130, may act centrally to decrease feeding. Another hypothesis is
that rhIL-11 might increase leptin levels as has been reported in vivo
for IL-1
and TNF-
(Ballinger, 1999
).
Inflammation induced an increase in passive tension, which opposes and
restores the original length of the muscle after release. Changes in
the extracellular matrix (edema, collagen, elastin fibers,
proteoglycans) to which smooth muscle fibers are attached may
contribute to changes in passive tension but in this study the decrease
in collagen content was already normalized by the lowest dose of
rhIL-11, whereas passive tension was only restored by the highest dose.
Thus, collagen content does not seem to be the major factor determining
the change of passive tension. However, our histological observations
show that the increased edema only disappears with higher doses of
rhIL-11 and therefore parallels the changes in passive tension. Edema
is caused by increased vascular permeability and this may be related to
an increase in inducible nitric oxide (Boughton-Smith et al., 1993
;
Miller et al., 1995
; Ribbons et al., 1995
). Because IL-11 can reduce
the production of nitric oxide, also in rabbits (Misra et al., 1996
;
Trepicchio et al., 1996
), through inhibition of nuclear
factor-
B-dependent transcriptional activation (Trepicchio et al.,
1997
), this may be the mechanism responsible for the gradual decrease
in edema and restoration of passive tension with increasing doses of
rhIL-11.
It may be noted that a decrease in collagen content also has been
described in the rectal mucosa from patients with ulcerative colitis
(UC; Hendel et al., 1986
; Graham et al., 1988
), whereas in the ileum of
patients with CD the opposite has been found (Graham et al., 1988
).
Changes in collagen content may be caused by either changes in collagen
production or changes in collagen degradation. Interestingly, Matthes
et al. (1992)
demonstrated by in situ hybridization that the RNA
transcript levels of procollagen types I, III, IV, and V were higher in
UC compared with CD, yet the collagen deposition, as determined by
immunohistology, was lower in UC than in CD. This points to a different
metabolism of procollagen in UC and CD. Although IL-11 is a
fibroblast-derived cytokine not much is known about its effect on
collagen metabolism. Our study suggests that IL-11 increases collagen
deposition because the decrease in collagen content caused by colitis
was normalized by rhIL-11. This is in agreement with the observation
that targeted expression of IL-11 in the mouse airway causes airway
remodeling with increased types III and I collagen and local
accumulation of fibroblasts (Tang et al., 1996
). One way in which IL-11
could favor collagen deposition is by inducing the production of tissue
inhibitors of metalloproteinases, the enzymes involved in collagen
catabolism (Maier et al., 1993
). This topic also deserves further study
because the opposite effects on collagen content observed in patients with IBD may explain why in UC the bowel has the tendency to dilate and
perforate, whereas stricture formation is more common in CD.
Maximum tension occurred at smaller degrees of stretch in inflamed tissue. Optimal stretch is also a function of the elastic components of the muscle, the connective tissues, and the contractile filament content. rhIL-11 apparently did not restore the changes in these parameters.
The decreased maximal active tension to motilin and SP was normalized
by treatment with 40 µg/kg · day rhIL-11. This dose also restores
the continuity of the smooth muscle layer so that an optimal contact
between neighboring smooth muscle cells is reached. However, changes in
tension also were reflected by changes in motilin and SP receptor
density, indicating effects at the receptor level and suggesting the
presence of a cytokine response element in the promotor region of the
motilin and SP receptor. For motilin the receptor affinity was not
affected, but for SP the affinity for the high-affinity binding site
was increased. These sites probably do not represent different subtypes
of SP receptors because the binding can only be displaced by SP and the
neurokinin (NK)1 agonist
[
Ala4,Sar9,Met(O2)11]-SP(4-11)
but not by the NK2 agonist
[
Ala8]-neurokinin A (4-10) or
NK3 agonist
[MePhe7]-neurokinin B (our unpublished
data). Furthermore, Koelbel et al. (1989)
have shown that the
myogenic response of the distal colon of the rabbit appears to be
mediated through NK1 receptors. It is rather
likely that the high- and low-affinity binding site represent,
respectively, neural and smooth muscle SP receptors. In rats with TNBS
colitis SP receptors also are down-regulated (Evangelista et al.,
1996
), but in patients with IBD, SP receptors in the circular muscle
are unaffected but are up-regulated in the lymphoid aggregates, small
blood vessels, and myenteric neurons (Mantyh et al., 1995
).
The response to KCl, which acts independent of a receptor, also was normalized by rhIL-11, suggesting that rhIL-11 interferes with the contractile apparatus itself. A higher dose of rhIL-11 was needed to reestablish the response to ACh and KCl than to motilin and SP, suggesting that general smooth muscle damage is not the main cause for the decreased contractility. However, the lowest dose of rhIL-11 already normalized the increased contractile potency to ACh. That different doses are required to restore different parameters may be due to the fact that factors involved in receptor regulation, transduction, or Ca2+ handling properties have a different susceptibility to IL-11, but are of different importance for the respective contractile agents. Furthermore, the magnitude of the tension that has to be restored is higher for ACh and KCl than for motilin and SP.
Whether the effects of rhIL-11 represent direct effects or
involve other inflammatory mediators is not known. It has been shown
that in rabbits with TNBS colitis PGE2 levels are
significantly increased within 6 h of exposure to TNBS and remain
elevated for at least 10 days (Mellman et al., 1990
). We found that
COX-2 mRNA expression was increased in the colonic muscle layer of
inflamed rabbits and was not affected by rhIL-11 treatment.
Desensitization may therefore be responsible for the reduced
contractile response to PGE2 observed in our
study. Also in rats the protective effects of rhIL-11 on colonic damage
induced by TNBS are not mediated by actions on the eicosanoid
metabolism (Qiu et al., 1996
). In the HLA-B27 rat, rhIL-11 treatment
reduces clinical signs and histological lesions of colitis that are
associated with down-regulation of the expression of inducible nitric
oxide synthase, IL-6, transforming growth factor-
, and of multiple
proinflammatory cytokines, including IL-12 p40, interferon-
,
IL-1
, TNF-
, and IL-1
(Peterson et al., 1998
). In this study we
demonstrated that in the colonic mucosa IL-RA expression was enhanced
by rhIL-11 treatment and that in the colonic muscle layer IL-1
and
IL-RA mRNA levels disappeared during therapy, supporting a role for
IL-1
in the impaired contractility observed during colitis but not
for TNF-
, which was decreased by the inflammatory process. It
remains to be investigated which other cytokines are involved.
In conclusion, rhIL-11 partially normalizes changes in contractile response toward receptor-specific (motilin, ACh, SP) and receptor-independent (KCl) stimuli. These findings suggest that this cytokine may contribute to the restoration of motor dysfunction in patients with IBD.
| |
Acknowledgment |
|---|
We thank Linda Nijs for skillful technical assistance.
| |
Footnotes |
|---|
Accepted for publication May 2, 2000.
Received for publication January 21, 2000.
1
This study was supported by grants from the Fund
for Scientific Research-Flanders (Belgium) (FWO Grant G 0109.00) and
the Belgian Ministry of Science (GOA 98/011 and IUAP P4/16). I.D. is a
postdoctoral research fellow of the Fund for Scientific
Research-Flanders. This work has been presented at the American
Gastroenterological Association in New Orleans (Depoortere et al.,
1998
).
Send reprint requests to: Theo L. Peeters, Centre for Gastroenterological Research, Gasthuisberg O & N, B-3000 Leuven, Belgium. E-mail: theo.peeters{at}med.kuleuven.ac.be
| |
Abbreviations |
|---|
IL, interleukin;
TNF-
, tumor necrosis
factor-
;
TNBS, 2,4,6-trinitrobenzene sulfonic acid;
CD, Crohn's
disease;
rhIL-11, recombinant human interleukin-11;
ACh, acetylcholine;
SP, substance P;
PGE2, prostaglandin E2;
IBD, irritable bowel disease;
IL-RA, interleukin receptor antagonist;
COX-2, cyclooxygenase-2;
PCR, polymerase chain reaction;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
UC, ulcerative colitis;
NK, neurokinin.
| |
References |
|---|
|
|
|---|
.
Biochem Biophys Res Commun
150:
1237-1243[Medline].
: Suppression of food intake by direct action in the central nervous system.
Brain Res
448:
106-114[Medline].
B.
J Immunol
159:
5661-5670[Abstract].
This article has been cited by other articles:
![]() |
K. Venkova, J. C. Keith Jr., and B. G.-V. Meerveld Oral Treatment with Recombinant Human Interleukin-11 Improves Mucosal Transport in the Colon of Human Leukocyte Antigen-B27 Transgenic Rats J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 206 - 213. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kinoshita, K. Sato, M. Hori, H. Ozaki, and H. Karaki Decrease in activity of smooth muscle L-type Ca2+ channels and its reversal by NF-{kappa}B inhibitors in Crohn's colitis model Am J Physiol Gastrointest Liver Physiol, August 8, 2003; 285(3): G483 - G493. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||